from Reuters: Health https://reut.rs/2D3xV5n
Tuesday, April 9, 2019
Regeneron forays into gene-silencing therapies with Alnylam tie-up
Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology.
from Reuters: Health https://reut.rs/2D3xV5n
from Reuters: Health https://reut.rs/2D3xV5n
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment